Open AccessODAC Recommends Approval of Iressa Despite Poor Response Rate & General Lack of Clinical Benefit
Author(s) -
Margot J. Fromer
Publication year - 2002
Publication title -
oncology times
Language(s) - English
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000289873.05778.91
Subject(s) - medicine , gefitinib , tolerability , docetaxel , clinical trial , carboplatin , population , oncology , lung cancer , clinical research , cancer , chemotherapy , adverse effect , cisplatin , epidermal growth factor receptor , environmental health